Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | NSCLC | Research

ANKRD49 promotes the metastasis of NSCLC via activating JNK-ATF2/c-Jun-MMP-2/9 axis

Authors: Jia Sun, Jin-rui Hu, Chao-feng Liu, Yuan Li, Wei Wang, Rong Fu, Min Guo, Hai-long Wang, Min Pang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Ankyrin repeat domain 49 (ANKRD49) has been found to be highly expressed in multiple cancer including lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC). However, the function of ANKRD49 in the pathogenesis of NSCLC still remains elusive. Previously, ANKRD49 has been demonstrated to promote the invasion and metastasis of A549 cells, a LUAD cell line, via activating the p38-ATF-2-MMP2/MMP9 pathways. Considering the heterogeneity of tumor cells, the function and mechanism of ANKRD49 in NSCLC need more NSCLC-originated cells to clarify.

Methods

Real-time qPCR was employed to test ANKRD49 expression levels in nine pairs of fresh NSCLC tissues and the corresponding adjacent normal tissues. The function of ANKRD49 was investigated using overexpression and RNA interference assays in lung adenocarcinoma cell line (NCI-H1299) and lung squamous carcinoma cell line (NCI-H1703) through gelatin zymography, cell counting kit-8, colony formation, wound healing, migration and invasion assays mmunoprecipitation was performed to in vitro. Immunoprecipitation was performed to test the interaction of c-Jun and ATF2. Chromatin immunoprecipitation was conducted to assess the transcriptional regulation of ATF2/c-Jun on MMP-2/9. Moreover, the tumorigenicity of ANKRD49 was evaluated in nude mice models and the involved signal molecular was also measured by immunohistochemical method.

Results

We found that the levels of ANKRD49 in cancerous tissues were higher than those in adjacent normal tissues. in vitro assay showed that ANKRD49 promoted the migration and invasion of NCI-H1299 and NCI-H1703 cells via enhancing the levels of MMP-2 and MMP-9. Furthermore, ANKRD49 elevated phosphorylation of JNK and then activated c-Jun and ATF2 which interact in nucleus to promote the binding of ATF2:c-Jun with the promoter MMP-2 or MMP-9. In vivo assay showed that ANKRD49 promoted lung metastasis of injected-NSCLC cells and the high metastatic rate was positively correlated with the high expression of ANKRD49, MMP-2, MMP-9, p-JNK, p-c-Jun and p-ATF2.

Conclusion

The present study indicated that ANKRD49 accelerated the invasion and metastasis of NSCLC cells via JNK-mediated transcription activation of c-Jun and ATF2 which regulated the expression of MMP-2/MMP-9. The molecular mechanisms of ANKRD49’s function is different from those found in A549 cells. The current study is a supplement and improvement to the previous research.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRefPubMed
2.
Keating GM. Nivolumab: a review in advanced squamous non-small cell Lung cancer. Drugs. 2015;75(16):1925–34.PubMedCrossRef
3.
Huang T, Li J, Zhang C, Hong Q, Jiang D, Ye M, Duan S. Distinguishing lung adenocarcinoma from lung squamous cell carcinoma by two hypomethylated and three hypermethylated genes: a Meta-analysis. PLoS ONE. 2016;11(2):e0149088.PubMedPubMedCentralCrossRef
4.
Rosell R, Karachaliou N. Lung cancer: maintenance therapy and precision medicine in NSCLC. Nat Rev Clin Oncol. 2013;10(10):549–50.PubMedCrossRef
5.
MacDonagh L, Gray SG, Breen E, Cuffe S, Finn SP, O’Byrne KJ, Barr MP. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett. 2018;428:117–26.PubMedCrossRef
6.
Wang HL, Fan SS, Pang M, Liu YH, Guo M, Liang JB, Zhang JL, Yu BF, Guo R, Xie J, et al. The ankyrin repeat domain 49 (ANKRD49) augments autophagy of serum-starved GC-1 cells through the NF-κB pathway. PLoS ONE. 2015;10(6):e0128551.PubMedPubMedCentralCrossRef
7.
Zhou X, Wang WT, Sun J, Liu HY, Bai XY, Liu JJ, Yu BF, Guo R, Wang HL. ANKRD49 inhibits etoposide-induced intrinsic apoptosis of GC-1 cells by modulating NF-κB signaling. Mol Cell Biochem. 2019;457(1–2):21–9.PubMedCrossRef
8.
Liu CG, Cui XL, Wei ZG, Guo JS. High expression of the ANKRD49 protein is associated with progression and poor prognosis of gastric cancer. Cancer Biomark. 2018;22(4):649–56.PubMedCrossRef
9.
Hao C, Duan H, Li H, Pei M, Liu Y, Fan Y, Zhang C. Up-regulation of ANKDR49, a poor prognostic factor, regulates cell proliferation of gliomas. Biosci Rep 2017, 37(4).
10.
Li XY, Qin KR, Liu YH, Pang M, Huo YK, Yu BF, Wang HL. A microarray study on the expression of ANKRD49 in lung squamous cell carcinoma and its clinicopathologic significance. Appl Immunohistochem Mol Morphol. 2022;30(6):418–24.PubMedCrossRef
11.
Liu YH, Yuan M, Xu BX, Gao R, You YJ, Wang ZX, Zhang YC, Guo M, Chen ZY, Yu BF, et al. ANKRD49 promotes the invasion and Metastasis of lung adenocarcinoma via a P38/ATF-2 signalling pathway. J Cell Mol Med. 2022;26(16):4401–15.PubMedPubMedCentralCrossRef
12.
Wang X, Yang B, She Y, Ye Y. The lncRNA TP73-AS1 promotes Ovarian cancer cell proliferation and Metastasis via modulation of MMP2 and MMP9. J Cell Biochem. 2018;119(9):7790–9.PubMedCrossRef
13.
Xu F, Li Q, Wang Z, Cao X. Sinomenine inhibits proliferation, migration, invasion and promotes apoptosis of Prostate cancer cells by regulation of miR-23a. Biomed Pharmacother. 2019;112:108592.PubMedCrossRef
14.
Feng X, Yan N, Sun W, Zheng S, Jiang S, Wang J, Guo C, Hao L, Tian Y, Liu S, et al. Mir-4521-FAM129A axial regulation on ccRCC progression through TIMP-1/MMP2/MMP9 and MDM2/p53/Bcl2/Bax pathways. Cell Death Discov. 2019;5:89.PubMedPubMedCentralCrossRef
15.
Zhou Z, Zhou Q, Wu X, Xu S, Hu X, Tao X, Li B, Peng J, Li D, Shen L, et al. VCAM-1 secreted from cancer-associated fibroblasts enhances the growth and invasion of Lung cancer cells through AKT and MAPK signaling. Cancer Lett. 2020;473:62–73.PubMedCrossRef
16.
Li S, Mai H, Zhu Y, Li G, Sun J, Li G, Liang B, Chen S. MicroRNA-4500 inhibits Migration, Invasion, and angiogenesis of Breast Cancer cells via RRM2-Dependent MAPK signaling pathway. Mol Ther Nucleic Acids. 2020;21:278–89.PubMedPubMedCentralCrossRef
17.
Wei CH, Wu G, Cai Q, Gao XC, Tong F, Zhou R, Zhang RG, Dong JH, Hu Y, Dong XR. MicroRNA-330-3p promotes cell invasion and Metastasis in non-small cell Lung cancer through GRIA3 by activating MAPK/ERK signaling pathway. J Hematol Oncol. 2017;10(1):125.PubMedPubMedCentralCrossRef
18.
Min BW, Kim CG, Ko J, Lim Y, Lee YH, Shin SY. Transcription of the protein kinase C-delta gene is activated by JNK through c-Jun and ATF2 in response to the anticancer agent doxorubicin. Exp Mol Med. 2008;40(6):699–708.PubMedPubMedCentralCrossRef
19.
Li M, Zhang D, Ge X, Zhu X, Zhou Y, Zhang Y, Peng X, Shen A. TRAF6-p38/JNK-ATF2 axis promotes microglial inflammatory activation. Exp Cell Res. 2019;376(2):133–48.PubMedCrossRef
20.
Meng Q, Xia Y. c-Jun, at the crossroad of the signaling network. Protein Cell. 2011;2(11):889–98.PubMedCrossRef
21.
Liu JF, Chen PC, Chang TM, Hou CH. Monocyte chemoattractant Protein-1 promotes cancer cell migration via c-Raf/MAPK/AP-1 pathway and MMP-9 production in osteosarcoma. J Exp Clin Cancer Res. 2020;39(1):254.PubMedPubMedCentralCrossRef
22.
Oh JH, Joo YH, Karadeniz F, Ko J, Kong CS. Syringaresinol inhibits UVA-Induced MMP-1 expression by suppression of MAPK/AP-1 signaling in HaCaT keratinocytes and human dermal fibroblasts. Int J Mol Sci 2020, 21(11).
23.
24.
Gozdecka M, Breitwieser W. The roles of ATF2 (activating transcription factor 2) in tumorigenesis. Biochem Soc Trans. 2012;40(1):230–4.PubMedCrossRef
25.
Wang Y, Gao H, Cao X, Li Z, Kuang Y, Ji Y, Li Y. Role of GADD45A in myocardial ischemia/reperfusion through mediation of the JNK/p38 MAPK and STAT3/VEGF pathways. Int J Mol Med 2022, 50(6).
26.
Wu J, Zhang Y, Ding T, Cheng R, Gong W, Guo Y, Luo Y, Pan Y, Zhai Q, Sun W, et al. Napsin A expression in subtypes of thyroid tumors: comparison with Lung Adenocarcinomas. Endocr Pathol. 2020;31(1):39–45.PubMedCrossRef
27.
28.
Jones RA, Franks SE, Moorehead RA. Comparative mRNA and miRNA transcriptome analysis of a mouse model of IGFIR-driven Lung cancer. PLoS ONE. 2018;13(11):e0206948.PubMedPubMedCentralCrossRef
29.
Nobre AR, Albergaria A, Schmitt F. p40: a p63 isoform useful for Lung cancer diagnosis - a review of the physiological and pathological role of p63. Acta Cytol. 2013;57(1):1–8.PubMedCrossRef
30.
Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, Hsu PY, Wu G, Lin CH, Chang GC, Li KC, et al. A four-gene signature from NCI-60 cell line for survival prediction in non-small cell Lung cancer. Clin cancer Research: Official J Am Association Cancer Res. 2009;15(23):7309–15.CrossRef
31.
Duff D, Long A. Roles for RACK1 in cancer cell migration and invasion. Cell Signal. 2017;35:250–5.PubMedCrossRef
32.
Polacheck WJ, Zervantonakis IK, Kamm RD. Tumor cell migration in complex microenvironments. Cell Mol Life Sci. 2013;70(8):1335–56.PubMedCrossRef
33.
Mikami S, Oya M, Mizuno R, Kosaka T, Katsube K, Okada Y. Invasion and Metastasis of renal cell carcinoma. Med Mol Morphol. 2014;47(2):63–7.PubMedCrossRef
34.
35.
Yang HL, Thiyagarajan V, Shen PC, Mathew DC, Lin KY, Liao JW, Hseu YC. Anti-EMT properties of CoQ0 attributed to PI3K/AKT/NFKB/MMP-9 signaling pathway through ROS-mediated apoptosis. J Exp Clin Cancer Res. 2019;38(1):186.PubMedPubMedCentralCrossRef
36.
Jacob A, Jing J, Lee J, Schedin P, Gilbert SM, Peden AA, Junutula JR, Prekeris R. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of Breast cancer cells. J Cell Sci. 2013;126(Pt 20):4647–58.PubMedPubMedCentral
37.
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–49.PubMedCrossRef
38.
Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, Varol M, Jain A, Khan MA, Sethi G. Role of reactive oxygen species in Cancer Progression: Molecular mechanisms and recent advancements. Biomolecules 2019, 9(11).
39.
Wang J, Liu Q, Xiao H, Luo X, Liu X. Suppressive effects of Momordin Ic on HepG2 cell migration and invasion by regulating MMP-9 and adhesion molecules: involvement of p38 and JNK pathways. Toxicol in Vitro. 2019;56:75–83.PubMedCrossRef
40.
Ou S, Liao Y, Shi J, Tang J, Ye Y, Wu F, Wang W, Fei J, Xie F, Bai L. S100A16 suppresses the proliferation, migration and invasion of Colorectal cancer cells in part via the JNK/p38 MAPK pathway. Mol Med Rep 2021, 23(2).
41.
Lin Z, Huang Q, Liu J, Wang H, Zhang X, Zhu Z, Zhang W, Wei Y, Liu Z, Du W. Interleukin-17D promotes Lung cancer progression by inducing tumor-associated macrophage infiltration via the p38 MAPK signaling pathway. Aging. 2022;14(15):6149–68.PubMedPubMedCentralCrossRef
42.
Hinz TK, Kalkur R, Rabinovitch J, Hinkle W, Heasley LE. TP53 null mutations identify Lung Cancer Cell lines with highest sensitivity to the nontaxane microtubule inhibitor eribulin. Mol Pharmacol. 2021;100(2):144–54.PubMedCrossRef
43.
Li S, Ung TT, Nguyen TT, Sah DK, Park SY, Jung YD. Cholic Acid stimulates MMP-9 in human Colon Cancer cells via activation of MAPK, AP-1, and NF-κB activity. Int J Mol Sci 2020, 21(10).
44.
45.
Pant I, Rao SG, Kondaiah P. Role of areca nut induced JNK/ATF2/Jun axis in the activation of TGF-β pathway in precancerous oral Submucous Fibrosis. Sci Rep. 2016;6:34314.PubMedPubMedCentralCrossRef
46.
Watson G, Ronai ZA, Lau E. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and Disease. Pharmacol Res. 2017;119:347–57.PubMedPubMedCentralCrossRef
47.
Lindaman LL, Yeh DM, Xie C, Breen KM, Coss D. Phosphorylation of ATF2 and interaction with NFY induces c-Jun in the gonadotrope. Mol Cell Endocrinol. 2013;365(2):316–26.PubMedCrossRef
48.
Tombulturk FK, Soydas T, Sarac EY, Tuncdemir M, Coskunpinar E, Polat E, Sirekbasan S, Kanigur-Sultuybek G. Regulation of MMP 2 and MMP 9 expressions modulated by AP-1 (c-jun) in wound healing: improving role of Lucilia Sericata in diabetic rats. Acta Diabetol. 2019;56(2):177–86.PubMedCrossRef
Metadata
Title
ANKRD49 promotes the metastasis of NSCLC via activating JNK-ATF2/c-Jun-MMP-2/9 axis
Authors
Jia Sun
Jin-rui Hu
Chao-feng Liu
Yuan Li
Wei Wang
Rong Fu
Min Guo
Hai-long Wang
Min Pang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11612-9

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Changing patterns of nasopharyngeal carcinoma incidence in Hong Kong: a 30-year analysis and future projections

Study Protocol

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

Research

Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways

Research

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

Research

Tumor residue in patients with stage II–IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein–Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose

Research

PSMD1 as a prognostic marker and potential target in oropharyngeal cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits